Conditional sentence

Irish families have changed — it’s a shame the constitution won’t be amended to reflect that

Retrieved on: 
Wednesday, March 13, 2024

Voters also rejected a second referendum on changing wording about a woman’s “duties in the home”.

Key Points: 
  • Voters also rejected a second referendum on changing wording about a woman’s “duties in the home”.
  • The change would have reflected the diversity of families in contemporary Ireland, and granted equal constitutional rights to single parents.
  • By 2022, the last Irish census, 45% of all family units were defined as a married couple with children.
  • But my research shows that marriage itself isn’t, on its own, necessarily the most important factor for family or child wellbeing.

Marriage isn’t everything

  • I’m a sociologist who studies family life, marriage and relationships.
  • My analysis of this data, with colleagues, shows that marriage isn’t the most important factor in determining whether children thrive.
  • One-parent families were largely lone mother families with 9% defined as “never married” lone mothers and 8% as “previously married”.
  • The children born to never married mothers tend on average to weigh less than those born to married mothers.
  • Families differ for many reasons besides marriage.
  • In other words, we estimated that most of the difference was due to the socioeconomic resources available to families, rather than to marriage itself.


Carmel Hannan receives funding from the Family Support Agency administered
through the Irish Research Council

EQS-News: Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Retrieved on: 
Wednesday, March 13, 2024

BERKELEY, US – MAINZ, Germany – February 21st, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – February 21st, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy.
  • TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan.
  • "TomaLab is the ideal partner to bring our pioneering product to Italy given its state-of-the-art facilities and commitment to innovative healthcare solutions, " said Guido Baechler, CEO of Mainz Biomed.
  • "We are thrilled to collaborate with Mainz Biomed to incorporate ColoAlert® into our laboratory procedures."

HIMALAYA TECHNOLOGIES PARTNERS WITH RENOVI! TO TARGET MEDICAL TOURISM MARKET IN CARIBBEAN; ADDS CEO TO ADVISORY BOARD

Retrieved on: 
Monday, March 11, 2024

Additionally, the Company has appointed Renovi!’s CEO, David Burns, Ph.D., to its Advisory Board to guide its entry into this multi-billion dollar market, assist on mergers and acquisitions including a potential combination of Renovi!

Key Points: 
  • Additionally, the Company has appointed Renovi!’s CEO, David Burns, Ph.D., to its Advisory Board to guide its entry into this multi-billion dollar market, assist on mergers and acquisitions including a potential combination of Renovi!
  • The availability of the newest medical technologies and the cheaper cost of treatment in emerging nations are key market drivers enhancing market growth.
  • reinvents traditional outpatient rehabilitation by offering patients a “recovery vacation” at an upscale, beachfront medical resort with healthy diet, exercise, community and exceptional medical care.
  • The Dominican Republic is uniquely positioned as a medical tourism destination because of its low costs, proximity to the U.S., a well-established tourism infrastructure, and tax incentives for tourism investments.

AAFA Statement on Asthma Inhaler Price Caps

Retrieved on: 
Friday, March 8, 2024

Boehringer Ingelheim announced it will cap out-of-pocket costs of its COPD and asthma inhaler portfolio at $35 per month for patients who have commercial insurance or no insurance.

Key Points: 
  • Boehringer Ingelheim announced it will cap out-of-pocket costs of its COPD and asthma inhaler portfolio at $35 per month for patients who have commercial insurance or no insurance.
  • “The announced price cap from Boehringer Ingelheim is a step toward improving access to essential asthma medicine and demonstrates that the voice of the asthma patient community is being heard,” states Kenneth Mendez, president and CEO of AAFA.
  • “AAFA will continue to advocate that all stakeholders in the drug pricing ecosystem take steps to improve affordability and access for life-saving medicines.”
    Last fall, AAFA shared patient stories and its Asthma Disparities in America report with the Senate Health, Education, Labor, and Pensions (HELP) Committee which then launched an investigation into the high price of asthma inhalers early this year.
  • In addition to pharmaceutical manufacturers, pharmacy benefit managers, insurance companies, employers, and federal policies all affect the final price paid for medicines.

Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.

Retrieved on: 
Thursday, March 7, 2024

GRANTS, NM, March 07, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation, a Delaware corporation (the “Company”), announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances. The application is an official and substantial step in Bright Green's expansion into the legal manufacturing of plant-based controlled substances including psilocybin, peyote, ibogaine, coca leaves, and opium poppy, alongside their active pharmaceutical ingredients ("API") for medical, research, and other legal purposes. The move aligns with Bright Green's commitment to providing a domestic supply of essential medications, addressing critical concerns associated with disruptions to the global pharmaceutical supply chain, and the national security risk currently posed by the United States’ dependency on imports.

Key Points: 
  • GRANTS, NM, March 07, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation, a Delaware corporation (the “Company”), announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances.
  • Last year, Bright Green obtained its DEA Registration for the Bulk Manufacturing of Cannabis, a Schedule I Controlled Substance, and recently received approval from the New Mexico Board of Pharmacy to produce additional Schedule I and Schedule II Controlled Substances.
  • The Company has assembled a team of experienced professionals to lead its controlled substance production efforts, ensuring adherence to stringent security and compliance standards.
  • The submission of this registration marks a significant milestone for Bright Green Corporation as it pioneers the “Drugs Made in America” movement.

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Thursday, March 7, 2024

ET –

Key Points: 
  • ET –
    WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and highlighted recent corporate developments.
  • “2023 was an exceptional year of execution and results for EyePoint Pharmaceuticals.
  • Review of Results for the Fourth Quarter Ended December 31, 2023
    For the quarter ended December 31, 2023, total net revenue was $14.0 million compared to $10.5 million for the quarter ended December 31, 2022.
  • ET to discuss the results for the fourth quarter and year ended December 31, 2023 and recent corporate developments.

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Retrieved on: 
Wednesday, March 6, 2024

EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024.

Key Points: 
  • EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024.
  • Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015.
  • Mr. Purcell also currently serves as a financial advisor to several emerging growth companies.
  • Mr. Purcell has worked on a number of company boards and has served on the Board of Directors of CFG Bank since 2016, the Board of Directors of Hyperion Bank since 2018, and the Board of Directors of International Money Express, Inc. since 2018.

Morphic to Participate in March Investor Conferences

Retrieved on: 
Tuesday, March 5, 2024

WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.

Key Points: 
  • WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.
  • A live webcast of the panel discussion and fireside chat at the TD Cowen 44th Annual Health Care Conference will be available on the Investor section of Morphic’s website at www.morphictx.com .
  • An archived replay will be available on the company’s website following the conference.

Noom Earns Highest CDC Recognition for Diabetes Prevention Program

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better and healthier lives, announced today that it has earned the Centers for Disease Control and Prevention's (CDC) highest honor, known as Full Plus Recognition for Noom's Diabetes Prevention Program (DPP).

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better and healthier lives, announced today that it has earned the Centers for Disease Control and Prevention's (CDC) highest honor, known as Full Plus Recognition for Noom's Diabetes Prevention Program (DPP).
  • Noom's retention and outcomes programs met stringent criteria in order to attain CDC Full Plus Recognition.
  • Noom's DPP is uniquely poised to address this widespread issue by offering organizations and individuals a solution to self-identify and engage in the highest quality standard in diabetes prevention, now endorsed by the CDC.
  • For more information about Noom's Diabetes Prevention Program and its CDC Full Plus Recognition, visit www.noom.com/diabetes-prevention-program .

CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

Retrieved on: 
Monday, March 4, 2024

Seladelpar is an investigational, potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, in development for PBC treatment.

Key Points: 
  • Seladelpar is an investigational, potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, in development for PBC treatment.
  • The study’s primary endpoint measure reflects registrational studies of the current second line PBC treatment authorized by the EMA.
  • In this study seladelpar demonstrated statistically significant improvements in biochemical markers of disease progression and PBC-related pruritus (itch) pre-specified endpoints.
  • “Validation of the European Marketing Authorization Application for seladelpar and the start of the agency’s formal review is an important step forward in seladelpar’s journey to potential approval in Europe.